Dose: 57.14 to 171.42 mg/kg
Single Dose: 110 (114.28)
Frequency: 12 hourly
Route: PO
Instructions: -

Dose: 170 mg/kg
Single Dose: 170 (170)
Frequency: 12 hourly
Route: oral
Instructions:

Dose: 150 to 250 mg/kg
Single Dose: 200 (200)
Frequency: 12 hourly
Route: Oral
Instructions: -

Cholestyramine also known as Colestyramine. . It is of Synthetic origin and belongs to Anion Exchange Resin. It belongs to Lipid lowering agents pharmacological group on the basis of mechanism of action and also classified in Antilipemic Agent pharmacological group.It is weakly acidic drug.

Cholestyramine is contraindicated in conditions like Intestinal obstruction,Diverticulitis,Anal fissure,Hernia,Dysphagia,Hemorrhagic diathesis.

Cholestyramine produces potentially life-threatening effects which include Intestinal impaction, Bleeding diathesis. which are responsible for the discontinuation of Cholestyramine therapy.The symptomatic adverse reactions produced by Cholestyramine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Nausea, Vomiting, Diarrhea, Constipation, Rashes, Heart burn, Abdominal discomfort.

Cholestyramine is primarily indicated in conditions like Bile-induced gastritis, Diarrhoea, Diarrhoea syndromes, Digitalis intoxication, Familial hypercholesterolaemia, Hypercholesterolaemia, Hyperlipidaemias, Hyperlipoproteinaemia, L-thyroxine intoxication, Prophylaxis of NSAID-associated gastric or duodenal ulcer, Pruritus, Thyrotoxicosis.

Cholestyramine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAcarboseAlfacalcidolit interferes with its actionBendrofluazideBenorylateBudesonideCalcifediolCalciferolCalcitriolCerivastatin SodiumCerivastatin sodium has its effect moderately reduced by CholestyramineChenodeoxycholic AcidCiprofibrateCyanocobalaminDiclofenac (K)Diclofenac (Na)cholestyramine reduce bioavailability of diclofenacDigitoxinDigoxinCholestyramine may decrease the absorption of digoxin.ModerateGive digoxin 8 hours before agent or use solution or liquid-filled capsule form of digoxin.DutasterideIncreased the AUC and Cmax ofdutasteride by approximately 10%.FluvastatinHydrochlorothiazideIt will reduce absorption of Hydrochlorothiazide from GIHydrocortisoneIopanoic AcidIpodateCholestyramine may bind to oral iodine contrast agents and interfere with diagnostic testing. It is recommended that cholestyramine be discontinued prior to imaging with iodine contrast agents.MinorLoperamide (HCl)MycophenolateConcurrent use decrease the AUC approximately 40%.PhenprocoumonDue to enterohepatic cycling and the long half-life of phenprocoumon, an interaction between these two drugs could not be avoided. We therefore recommend that cholestyramine not be administered to patients treated with drugs undergoing enterohepatic cycling, such as oral anticoagulants.Phenylbutazone Propranolol (HCl)QuinidineRaloxifene (HCl)SulphasalazineThyroxine (Na)Thyroxine (Na)TorasemideCholestyramine may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.TroglitazoneValproic AcidCoadministration of these drugs may lead to abnormal bleeding due to inability of blood to clot. Cholestyramine may reduce the absorption of valproic acid from intestine result in therapeutic inefficacy.Vitamin KWarfarin (Na)Cholestyramine reduces the anticoagulant effect of warfarin by decreasing absorption and increasing its elimination. ModerateClosely monitor for prothrombin time and INR . warfarin should administer at least one hour before or 4-6 hours after cholestyramine.Patient should report the sign of bleeding or clot to physician. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Powder Store in a well closed container, Below 40°C. Protect from Moisture.

Before starting therapy with cholestyramine, investigate and treat diseases like diabetes mellitus, hypothyroidism, dysproteinemias or liver diseases. With long term therapy, supplemental vitamin A and D may be given. Periodically measure serum triglyceride level to detect significant changes. These agents may produced or severely worsen pre-existing constipation. A laxative, stool softener or increased fluid intake may be helpful.